This study mainly to observe the anti angiogenic drugs Endostatin (Endostar) combined with vinorelbine and Cisplatin (NP) as neoadjuvant therapy in patients with non small cell lung cancer clinical efficiency and safety. Through anti angiogenesis therapy combined with neoadjuvant chemotherapy improve the treatment of neoadjuvant therapy in tumor response rate and the rate of resection, At the same time, the study before and after the anti angiogenesis therapy in patients with peripheral blood circulation endothelial cells(CECs), levels of Endothelial progenitor cells（EPC）, micro vascular density（MVD） and vascular endothelial growth factor(VEGF) expression level, to understanding the correlation between the clinical efficacy of anti angiogenesis therapy combined with chemotherapy and the change of all these markers. In order to find the reference basis for the prediction of the effect of curative effect. The changes of blood volume, blood flow and vascular permeability of the lung cancer before and after treatment with CT perfusion imaging are studied.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
30
Endostatin,7.5mg/m\^2,intravenous, d1-14;
vinorelbine,25mg/m\^2,intravenous, d1, d8;
Cisplatin，75mg/m\^2 intravenous,divide into d1-3
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China
Tumor Regression Rate
Target lesion size reduction ratio
Time frame: 3 months
Disease free survival is defined as the time from randomization to disease recurrence or death which comes first.
Time frame: 5 years
Overall Survival
the time from randomization to death.
Time frame: 5 years
Clinical Benefit Rate
Time frame: 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.